研究单位：[1]Peking University Cancer Hospital & Institute[2]Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute,Beijin,Beijing,China,100142[3]Department of Gastroenterology and Hepatology, The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China[4]Department of Oncology, The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China[5]Medical Oncology Department of Gastrointestinal Cancer, Liaoning Cancer Hospital & Institute,Shengyang,Liaoning,China[6]Department of Oncology, The Affiliated Hospital of Qingdao University,Qingdao,Shandong,China[7]Department of Gastroenterology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital,Taiyuan,Shanxi,China[8]Department of Medical Oncology, Peking University First Hospital,Beijing,China[9]Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University,Beijing,China[10]Department of Oncology, Peking University Shougang Hospital,Beijing,China[11]Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital,Tianjin,China
研究目的：
This study is a multi-center, non-interventional, prospective clinical observational study, aiming to evaluate the effectiveness and safety of subsequent treatment in dMMR/MSI solid tumor patients who have never received ICIs under real-world conditions. Particular attention is paid to the efficacy in populations where treatment plans are adjusted based on ctDNA, and potential predictive or prognostic biomarkers are explored.
